Trial reportKidney3602026
Dapagliflozin Mitigates Medullary Hypoxia in CKD Patients: Analysis of Blood Oxygenation Level-Dependent Magnetic Resonance Imaging Renal Data from the Randomized Glucose Transport and Renal Protection in CKD Trial.
Trial report in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05998837. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Single-center, Randomized, Controlled Study to Evaluate the Effects of a Six-month Treatment With Renal Glucose Transport Inhibitor (SGLT2i) Drugs on Markers of Senescence, Inflammation and Tubulointerstitial Damage in the Kidney of Patients With Chronic Kidney Disease With or Without Type 2 Diabetes
Open the trial in the graphWho cites it
4 citing papers in PubMed.
- Dapagliflozin Reduces Ambulatory Arterial Stiffness Index in CKD Patients with and Without Diabetes Independently of Blood Pressure Control: Results from the GLUcose Transport and Renal PROtection in Chronic Kidney Disease (GLUTREPRO) Trial.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Trial
- Gouty kidney disease: a tubulointerstitial paradigm reimagined-early detection, precision stratification, and targeted intervention.Rheumatology international · 2026Review
- The Impact of Sodium Glucose Transporter 2 Inhibitors on Renal Parenchymal Oxygenation: An Unsettled Issue?Kidney360 · 2026Article
- Antiproteinuric effect of dapagliflozin attenuates tubule-interstitial injury development in subclinical acute kidney injury animal model.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
key pointsDapagliflozin significantly improves renal medullary oxygenation in CKD, constituting a potential mechanism of its nephroprotection. The enhancement of medullary oxygenation is more pronounced in nondiabetic patients, suggesting a distinct pathophysiologic response. Blood oxygenation level-dependent magnetic resonance imaging represents a promising noninvasive biomarker for assessing renal oxygenation.
backgroundRenal hypoxia is believed to play a central role in the pathophysiology of both diabetic and nondiabetic CKD. Dapagliflozin has been shown to slow the progression of kidney disease by counteracting several pathogenic mechanisms. The advent of blood oxygenation level-dependent magnetic resonance imaging (BOLD-MRI) has enabled the noninvasive assessment of renal oxygenation in humans. However, it remains uncertain whether dapagliflozin affects changes in renal oxygenation. The aim of the study was to assess whether dapagliflozin modifies kidney oxygenation measured by BOLD-MRI.
methodsThe GLUcose Transport and Renal PROtection in chronic kidney disease study is a randomized controlled clinical trial investigating the effect of dapagliflozin on kidney measures. Here, we investigate whether changes in global and segmental renal oxygenation estimated by BOLD-MRI (namely, changes in R2* parameter) can be measured, after randomization to dapagliflozin or placebo. We analyzed data from 720 pairs of regions of interest of 20 patients who underwent BOLD-MRI on a 3T magnetic resonance imaging scanner, comparing baseline measurements against the ones obtained after 3 months from the onset of treatment.
resultsAfter 12 weeks, dapagliflozin treatment significantly reduced the medullary R2* relaxation rate, indicating improved oxygenation ( P = 0.015), while cortical R2* remained unchanged ( P = 0.56). This effect was more pronounced in nondiabetic patients. Dapagliflozin was identified as the sole independent determinant of improved medullary renal oxygenation ( β , -14.4; 95% confidence interval, -23.9 to -4.89; P = 0.003) after accounting for other confounding factors such as age, presence of diabetes or macroalbuminuria, and BP levels. In addition, dapagliflozin appeared to alter the relationship between changes in renal oxygenation and the eGFR slope.
conclusionsThese findings suggest that dapagliflozin may mitigate medullary hypoxia in patients with CKD. BOLD-MRI could serve as a valuable biomarker for assessing renal functional reserve and predicting CKD progression. Further studies are warranted to confirm these effects and explore underlying molecular mechanisms. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: EudraCT, 2020-004835-26 ; ClinicalTrials.gov, NCT05998837 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.